疑似阿片类药物过量后纳洛酮用量与芬太尼、赛拉嗪、中枢神经系统抑制剂及兴奋剂暴露的关系:一项初步研究
该初步观察性研究纳入2022年10月至2025年1月美国两家城市急诊科收治的106例疑似阿片类药物过量成人,比较到达急诊前给予的纳洛酮肠外等效剂量与血中芬太尼、赛拉嗪、中枢神经系统抑制剂及兴奋剂浓度的关系。72%可检出芬太尼,49%可检出赛拉嗪,44%可检出中枢神经系统抑制剂,74%可检出兴奋剂。纳洛酮总肠外等效剂量均值3.45 mg(SD 2.13),中位数4.0(IQR 2-4),首剂均值1.98(SD 1.1),中位数2.0(IQR 2-2)。芬太尼浓度第4四分位者纳洛酮用量4.67 mg,高于第3、2、1四分位的4.67、3.22、2.74 mg(所有比较p<0.01);赛拉嗪浓度第4四分位者纳洛酮用量5.03 mg,高于第3、2、1四分位的3.35、2.92、3.27 mg,但未达统计学显著(p>0.05)。
要点
- 疑似阿片类药物过量成人院前纳洛酮总肠外等效剂量中位数为4.0 mg(IQR 2-4),首剂中位数2.0 mg(IQR 2-2)。
- 芬太尼浓度第4四分位者纳洛酮用量4.67 mg,高于第3、2、1四分位的4.67、3.22、2.74 mg(所有比较p<0.01)。
- 赛拉嗪浓度第4四分位者纳洛酮用量5.03 mg,高于第3、2、1四分位的3.35、2.92、3.27 mg,但未达统计学显著(p>0.05)。
- 赛拉嗪浓度随芬太尼浓度升高呈中度增加(Spearman ρ=0.45,p<0.001)。
- 106例中72%可检出芬太尼,49%可检出赛拉嗪,44%可检出中枢神经系统抑制剂,74%可检出兴奋剂。
适用人群与场景
- 美国两家城市学术型急诊科收治的疑似阿片类药物过量成人(≥18岁),招募时间2022年10月至2025年1月。
研究设计与关键结果
- 初步观察性研究,纳入106例疑似阿片类药物过量成人,比较到达急诊前纳洛酮肠外等效剂量与血中芬太尼、赛拉嗪、中枢神经系统抑制剂及兴奋剂浓度。
- 纳洛酮总肠外等效剂量均值3.45 mg(SD 2.13),中位数4.0(IQR 2-4);首剂均值1.98 mg(SD 1.1),中位数2.0(IQR 2-2)。
- 芬太尼浓度第4四分位者纳洛酮用量4.67 mg,高于第3、2、1四分位的4.67、3.22、2.74 mg(所有比较p<0.01)。
- 52例赛拉嗪暴露者中,赛拉嗪浓度第4四分位者纳洛酮用量5.03 mg,高于第3、2、1四分位的3.35、2.92、3.27 mg,但未达统计学显著(p>0.05)。
- 赛拉嗪浓度随芬太尼浓度升高呈中度增加(Spearman ρ=0.45,p<0.001)。
证据类型、等级与局限
- 证据类型:初步观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在芬太尼流行区,疑似阿片类药物过量者院前所需纳洛酮典型剂量为4 mg,合并赛拉嗪暴露时剂量相似,但赛拉嗪浓度较高时纳洛酮用量趋于更高。
- 芬太尼浓度较高时赛拉嗪浓度也较高,解读赛拉嗪与纳洛酮剂量的关系时需考虑芬太尼共存的影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: In this pilot, observational study, we characterized naloxone doses individuals received after suspected opioid overdoses in comparison to concentrations of fentanyl, xylazine, central nervous system (CNS) depressants, and stimulants detected in their blood.
METHODS: Adults (≥ 18 years old) with suspected opioid overdose presenting to two academic urban US emergency departments (EDs) were recruited between October 2022 and January 2025. Naloxone parenteral equivalents administered prior to ED arrival were compared to fentanyl and xylazine as well as to CNS depressant (e.g., benzodiazepines) and stimulant (e.g., cocaine) blood concentrations.
RESULTS: Of the 106 participants, 72% had detectable concentrations of fentanyl; 49% xylazine; 44% CNS depressants; and 74% stimulants. Total mean naloxone parenteral equivalents administered were 3.45 mg (SD 2.13), median 4.0 (IQR 2-4), and mean first dose was 1.98 (SD 1.1), median 2.0 (IQR 2-2). Xylazine concentrations increased moderately as fentanyl concentrations increased (Spearman ρ = 0.45, p < 0.001). Participants whose fentanyl concentrations were in the 4th quartile had received more naloxone (4.67 mg) than those with fentanyl concentrations in the 3rd, 2nd, and 1st quartiles (4.67, 3.22, and 2.74 mg of naloxone, respectively) (p < 0.01 for all comparisons). Of the 52 participants exposed to xylazine, those with xylazine concentrations in the 4th quartile generally had received more naloxone (5.03 mg) than those in the 3rd, 2nd, and 1st xylazine quartiles (3.35, 2.92, and 3.27 mg of naloxone, respectively), but these comparisons did not reach statistical significance (p > 0.05).
CONCLUSIONS: The typical dose of naloxone needed in suspected opioid overdoses within a fentanyl endemic area was 4 mg. This dose was similar when xylazine co-exposure occurred, although it tended to be higher with higher xylazine concentrations detected. However, fentanyl was also present at higher levels when greater amounts of xylazine were present.
参考来源
- Merchant RC, Chapman B, Martinez PM, et al. Naloxone Administration in Relation to Fentanyl, Xylazine, CNS Depressants, and Stimulants Exposure After Suspected Opioid Overdose: A Pilot Study. Acad Emerg Med. 2026. PMID: 41931114. doi:10.1111/acem.70280
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。